Your browser is no longer supported. Please, upgrade your browser.
FBIO Fortress Biotech, Inc. monthly Stock Chart
Fortress Biotech, Inc.
Index- P/E- EPS (ttm)-0.85 Insider Own0.20% Shs Outstand76.09M Perf Week-2.83%
Market Cap242.83M Forward P/E- EPS next Y-0.56 Insider Trans29.96% Shs Float71.30M Perf Month15.55%
Income-56.70M PEG- EPS next Q-0.16 Inst Own33.70% Short Float3.18% Perf Quarter-30.47%
Sales43.00M P/S5.65 EPS this Y56.50% Inst Trans38.01% Short Ratio1.58 Perf Half Y-12.97%
Book/sh1.28 P/B2.15 EPS next Y25.30% ROA-22.30% Target Price- Perf Year33.50%
Cash/sh- P/C- EPS next 5Y25.50% ROE-102.70% 52W Range1.04 - 4.78 Perf YTD7.00%
Dividend- P/FCF- EPS past 5Y-5.40% ROI-79.70% 52W High-42.47% Beta2.35
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin67.70% 52W Low164.42% ATR0.18
Employees93 Current Ratio6.40 Sales Q/Q-3.10% Oper. Margin- RSI (14)49.31 Volatility7.54% 7.39%
OptionableNo Debt/Eq0.59 EPS Q/Q9.00% Profit Margin- Rel Volume0.56 Prev Close2.77
ShortableYes LT Debt/Eq0.59 Earnings- Payout- Avg Volume1.44M Price2.75
Recom2.00 SMA209.19% SMA50-11.05% SMA200-0.22% Volume801,191 Change-0.72%
Oct-02-20Initiated The Benchmark Company Buy $9
Dec-18-19Initiated B. Riley FBR Buy $9
Feb-28-18Initiated B. Riley FBR, Inc. Buy $10
Jul-11-17Initiated Rodman & Renshaw Buy $11
Mar-22-17Initiated JMP Securities Mkt Outperform
Oct-03-16Initiated ROTH Capital Buy $9
Nov-30-20 02:39PM  
Nov-27-20 05:58PM  
Nov-24-20 08:00AM  
Nov-23-20 08:00AM  
Nov-18-20 08:00AM  
Nov-17-20 12:41AM  
Nov-09-20 06:25PM  
Nov-06-20 04:20PM  
Nov-04-20 04:25PM  
Nov-03-20 12:30PM  
Nov-02-20 07:00AM  
Oct-26-20 08:00AM  
Oct-21-20 06:30AM  
Oct-19-20 08:30AM  
Oct-16-20 04:35AM  
Oct-14-20 09:08PM  
Oct-12-20 12:45PM  
Oct-08-20 08:00AM  
Oct-06-20 08:00AM  
Oct-01-20 08:00AM  
Sep-22-20 08:00AM  
Sep-18-20 09:03AM  
Sep-17-20 05:27PM  
Sep-14-20 08:00AM  
Sep-10-20 08:00AM  
Sep-09-20 08:00AM  
Sep-02-20 08:00AM  
Sep-01-20 11:26AM  
Aug-31-20 05:00PM  
Aug-28-20 08:30AM  
Aug-26-20 08:30PM  
Aug-12-20 07:30AM  
Aug-10-20 04:30PM  
Aug-05-20 03:34PM  
Aug-03-20 08:00AM  
Jul-31-20 07:30AM  
Jul-29-20 07:30AM  
Jul-21-20 08:30AM  
Jul-20-20 01:43PM  
Jun-29-20 08:30AM  
Jun-15-20 08:30AM  
Jun-11-20 09:00AM  
Jun-10-20 04:18PM  
Jun-05-20 08:30AM  
Jun-04-20 08:30AM  
Jun-02-20 08:30AM  
May-29-20 08:30AM  
May-26-20 09:30PM  
May-22-20 08:30AM  
May-12-20 08:00AM  
May-11-20 04:30PM  
May-08-20 07:30AM  
May-06-20 04:30PM  
Apr-30-20 07:30AM  
Apr-23-20 08:30AM  
Apr-21-20 08:00AM  
Apr-20-20 08:00AM  
Mar-30-20 07:30AM  
Mar-23-20 09:20AM  
Mar-18-20 06:39AM  
Mar-16-20 04:45PM  
Mar-11-20 04:15PM  
Feb-24-20 08:00AM  
Feb-18-20 08:00AM  
Feb-13-20 08:00AM  
Feb-11-20 08:00PM  
Jan-22-20 08:30AM  
Jan-17-20 08:07AM  
Jan-16-20 08:30AM  
Jan-13-20 08:15AM  
Dec-23-19 08:30AM  
Dec-16-19 07:28AM  
Dec-11-19 08:30AM  
Dec-09-19 07:30AM  
Dec-07-19 08:35AM  
Dec-02-19 08:30AM  
Dec-01-19 09:30AM  
Nov-25-19 08:00PM  
Nov-20-19 09:20AM  
Nov-19-19 04:01PM  
Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; MB-106, a CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101 that is in Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Hunter RobynChief Financial OfficerSep 22Sale4.3828,450124,611192,169Sep 25 06:37 PM
Hoenlein MalcolmDirectorAug 26Buy18.0016,667300,00616,667Sep 01 08:34 AM
ROSENWALD LINDSAY A MDPRESIDENT, CEO & CHAIRMANAug 26Buy18.0052,500945,00092,500Sep 01 08:32 AM